Regulatory Sourcebook eBook
Read the article:
The Real Danger of Substandard and Counterfeit COVID-19 Vaccines
Read the eBook:
Pharmaceutical Technology’s Regulatory Sourcebook eBook.
CONTINUE TO SITE
OR WAIT null SECS
Advertisement
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
The Real Danger of Substandard and Counterfeit COVID-19 Vaccines
Published on:
Meg Rivers
Pharmaceutical Technology, Pharmaceutical Technology, Regulatory Sourcebook, September 2021, Volume 2021 eBook, Issue 3
Pages: 10-14
Low- and middle-income countries are at the greatest risk of receiving substandard and falsified COVID-19 vaccines.
As the COVID-19 pandemic continues, one pressing concern for the industry is ensuring the supply of legitimate COVID-19 vaccines. Now more than ever, the supply chain needs to be secure to ensure the population can have access to legitimate vaccines. But substandard and falsified COVID-19 vaccines—commonly referred to as counterfeit vaccines—continue to be a threat globally.
Regulatory Sourcebook
Read this article in Pharmaceutical Technology’s September 2021 Regulatory Sourcebook eBook.
Advertisement
About the author
Meg Rivers is a senior editor at Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook, September 2021
September 2021
Pages: 10-14
Citation
When referring to this article, please cite it as M. Rivers, “The Real Danger of Substandard and Counterfeit COVID-19 Vaccines," Pharmaceutical Technology Regulatory Sourcebook eBook (September 2021).
